

# Kyowa Kirin Co., Ltd.

## Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 Third Quarter

(January 1, 2020 - September 30, 2020)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on October 30, 2020 for the first nine months of Fiscal 2020, from January 1, 2020 to September 30, 2020.
- This document is an English translation of the Japanese-language original. The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Due to the transfer of 95% of the shares of Kyowa Hakko Bio Co., Ltd. to Kirin Holdings Company, Limited. on April 24, 2019, the Bio-Chemicals business was categorized as a discontinued operation effective from the previous fiscal year for accounting on a consolidated basis. As a result, profit from discontinued operations is presented separately from continuing operations on the condensed quarterly consolidated statement of profit or loss, and the amounts displayed from "revenue" through "profit from continuing operations" are amounts of the continuing operations and exclude the discontinued operations.
- Figures presented in these materials have been rounded to the nearest tenth.
- Figures inside parenthesis presented in these materials indicate negative values.

Index	Page
I . Consolidated Financial Results	
1. Trends in consolidated profit	1
2. Revenue by location of customer	2
3. Revenue by regional control function	2
4. Capital expenditures and intangible assets investment	2
5. Depreciation and amortization	2
II . Consolidated Statement of Cash Flows	2
III . Revenue from Main Products	3
IV . R&D Pipeline	5

The average exchange rates for each period were as follows:

*Unit: Yen*

	FY 2019 results				FY 2020 results			FY 2020 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
USD	110	110	109	109	110	109	108	108
GBP	143	143	140	140	143	138	137	135

<p>Contact            Kyowa Kirin Co., Ltd.            Corporate Communications Department            Tel +81 3 5205 7206</p>
---

**I . Consolidated Financial Results**
**1. Trends in consolidated profit**

&lt;Accumulative&gt;

Unit: Billions of yer

	FY 2019 results				FY 2020 results				FY 2020 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec	Progress
Revenue	75.8	151.4	225.5	305.8	77.3	157.8	234.0	8.5	313.0	75%
Cost of sales	(19.8)	(38.6)	(57.1)	(79.6)	(19.4)	(41.0)	(58.6)	(1.6)	(77.0)	76%
Gross profit	56.1	112.8	168.4	226.2	57.9	116.9	175.4	7.0	236.0	74%
<i>Gross profit to revenue ratio</i>	74.0%	74.5%	74.7%	74.0%	74.9%	74.1%	74.9%	-	75.4%	-
Selling, general and administrative expenses	(26.7)	(55.3)	(83.9)	(117.3)	(29.7)	(58.2)	(88.1)	(4.3)	(123.0)	72%
Research and development expenses	(11.9)	(24.9)	(37.9)	(53.5)	(11.8)	(24.1)	(37.0)	0.8	(56.0)	66%
<i>R&amp;D expenses to revenue ratio</i>	15.7%	16.4%	16.8%	17.5%	15.3%	15.3%	15.8%	-	17.9%	-
Share of profit (loss) of investments accounted for using equity method	(0.2)	(0.5)	(0.9)	4.0	0.4	(0.1)	0.5	1.4	3.0	16%
Core operating profit	17.3	32.2	45.8	59.4	16.8	34.5	50.7	4.9	60.0	84%
<i>Core operating profit to revenue ratio</i>	22.9%	21.2%	20.3%	19.4%	21.7%	21.8%	21.7%	-	19.2%	-
Other income	0.1	0.2	0.3	0.4	0.2	0.7	1.0	0.7		
Other expenses	(5.3)	(10.5)	(12.3)	(15.0)	(1.9)	(5.3)	(8.7)	3.6		
Finance income (costs)	0.1	(0.0)	(0.3)	(0.3)	0.4	1.0	1.2	1.5		
Profit before tax	12.3	21.8	33.5	44.5	15.5	30.9	44.2	10.7	53.0	83%
Income tax expense	(3.0)	(3.2)	(6.5)	(6.8)	(1.7)	(3.1)	(6.7)	(0.2)	(9.0)	74%
<i>Ratio of income tax burden</i>	24.1%	14.5%	19.6%	15.3%	10.8%	10.0%	15.2%	-	17.0%	-
Profit from continuing operations	9.3	18.7	26.9	37.7	13.8	27.8	37.5	10.6	44.0	85%
<i>Profit from continuing operations to revenue ratio</i>	12.3%	12.3%	11.9%	12.3%	17.9%	17.6%	16.0%	-	14.1%	-
Profit from discontinued operations	(1.2)	29.4	29.4	29.4	-	-	-	(29.4)	-	-
Profit	8.1	48.1	56.3	67.1	13.8	27.8	37.5	(18.8)	44.0	85%
<i>Profit to revenue ratio</i>	10.7%	31.7%	25.0%	21.9%	17.9%	17.6%	16.0%	-	14.1%	-
EPS (¥/share)	14.97	89.02	104.48	124.57	25.78	51.76	69.80	(34.68)	81.92	-
Annual dividend (¥/share)				42.00					44.00	-
Dividend payout ratio (%)				33.7					53.7	-
ROE (%)				10.1					6.4	-

&lt;Quarterly&gt;

Unit: Billions of yer

	FY 2019 results				FY 2020 results			
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Revenue	75.8	75.6	74.0	80.4	77.3	80.5	76.2	2.1
Cost of sales	(19.8)	(18.9)	(18.5)	(22.5)	(19.4)	(21.5)	(17.7)	0.8
Gross profit	56.1	56.7	55.6	57.8	57.9	59.0	58.5	2.9
<i>Gross profit to revenue ratio</i>	74.0%	75.0%	75.1%	72.0%	74.9%	73.3%	76.8%	-
Selling, general and administrative expenses	(26.7)	(28.6)	(28.6)	(33.4)	(29.7)	(28.5)	(29.9)	(1.3)
Research and development expenses	(11.9)	(13.0)	(13.0)	(15.6)	(11.8)	(12.3)	(13.0)	0.0
<i>R&amp;D expenses to revenue ratio</i>	15.7%	17.1%	17.5%	19.5%	15.3%	15.2%	17.0%	-
Share of profit (loss) of investments accounted for using equity method	(0.2)	(0.3)	(0.4)	4.8	0.4	(0.5)	0.6	1.0
Core operating profit	17.3	14.8	13.6	13.6	16.8	17.7	16.2	2.6
<i>Core operating profit to revenue ratio</i>	22.9%	19.6%	18.4%	16.9%	21.7%	22.0%	21.3%	-
Other income	0.1	0.1	0.1	0.1	0.2	0.4	0.3	0.2
Other expenses	(5.3)	(5.2)	(1.9)	(2.7)	(1.9)	(3.4)	(3.4)	(1.5)
Finance income (costs)	0.1	(0.2)	(0.2)	(0.0)	0.4	0.7	0.2	0.4
Profit before tax	12.3	9.6	11.6	11.0	15.5	15.4	13.3	1.7
Income tax expense	(3.0)	(0.2)	(3.4)	(0.3)	(1.7)	(1.4)	(3.6)	(0.3)
Profit from continuing operations	9.3	9.3	8.3	10.8	13.8	14.0	9.7	1.4
<i>Profit from continuing operations to revenue ratio</i>	12.3%	12.4%	11.1%	13.4%	17.9%	17.3%	12.7%	-
Profit from discontinued operations	(1.2)	30.6	-	-	-	-	-	-
Profit	8.1	39.9	8.3	10.8	13.8	14.0	9.7	1.4
<i>Profit to revenue ratio</i>	10.7%	52.9%	11.1%	13.4%	17.9%	17.3%	12.7%	-

## 2. Revenue by location of customer

Unit: Billions of yen

	FY 2019 results					FY 2020 results				FY 2020 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of consolidated revenue	Jan - Mar	Jan - Jun	Jan - Sep	Percentage of consolidated revenue	Jan - Dec	Percentage of consolidated revenue
Japan	48.8	95.5	140.6	186.2	60.9%	43.4	86.0	124.8	53.3%	165.5	52.9%
International	27.1	55.9	84.9	119.6	39.1%	33.9	71.8	109.2	46.7%	147.5	47.1%
Americas	8.9	20.4	32.8	49.7	16.3%	15.8	32.5	50.9	21.7%	70.0	22.4%
Europe	11.8	22.0	31.7	42.2	13.8%	11.1	23.9	35.4	15.1%	46.5	14.9%
Asia	6.3	13.4	20.3	27.6	9.0%	7.0	15.2	22.8	9.7%	30.5	9.7%
Others	0.0	0.1	0.1	0.1	0.0%	0.0	0.2	0.1	0.1%	0.5	0.2%
Total consolidated revenue	75.8	151.4	225.5	305.8	100.0%	77.3	157.8	234.0	100.0%	313.0	100.0%

\* Revenue by location of customer is classified by region or country based on location of customer.

## 3. Revenue by regional control function

Unit: Billions of yen

	FY 2019 results				FY 2020 results				FY 2020 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec	Progress
Japan	45.9	90.3	132.0	174.7	41.1	82.1	119.5	(12.5)	158.0	75.6%
North America	7.0	16.3	26.5	39.0	13.2	27.6	43.7	17.2	56.0	78.0%
EMEA	11.2	22.2	32.1	42.9	11.6	25.1	36.3	4.1	46.0	78.8%
Asia/Oceania	5.4	11.4	17.3	23.1	5.8	12.3	19.1	1.8	26.0	73.6%
Others	6.4	11.2	17.5	26.0	5.5	10.7	15.4	(2.0)	27.0	57.2%
Total consolidated revenue	75.8	151.4	225.5	305.8	77.3	157.8	234.0	8.5	313.0	74.8%

\* Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin structure (a global management structure with axes combining four regions – Japan, North America, EMEA, and Asia/Oceania – and the functions needed by a global specialty pharmaceutical company).

\* EMEA consists of Europe, the Middle East, Africa, etc.

\* Others consists of technology out-licensing and original equipment manufacturing, etc.

## 4. Capital expenditures and intangible assets investment

Unit: Billions of yen

	FY 2019 results				FY 2020 results				FY 2020 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec	
Capital expenditures (property, plant and equipment)	2.6	4.5	5.7	8.2	3.1	5.1	6.9	12.8	12.8	
Intangible assets investment	3.4	3.7	13.2	14.4	0.1	13.5	19.7	21.1	21.1	
Total	6.0	8.2	18.9	22.6	3.2	18.6	26.6	33.9	33.9	

\* Acquisitions of right-of-use assets are not included.

## 5. Depreciation and amortization

Unit: Billions of yen

	FY 2019 results				FY 2020 results				FY 2020 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec	
Depreciation (property, plant and equipment)	2.5	5.5	8.1	10.7	2.9	5.8	8.5	11.3	11.3	
Amortization (intangible assets)	2.2	4.5	6.4	8.0	1.8	3.5	5.3	7.7	7.7	
Total	4.7	10.0	14.5	18.8	4.7	9.2	13.8	19.0	19.0	

## II. Consolidated Statement of Cash Flows

Unit: Billions of yen

	FY 2019 results				FY 2020 results				Change amount
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	
<b>Cash flows from operating activities</b>	9.2	19.8	38.6	53.7	0.6	20.6	31.9	(6.7)	
<i>Of which, cash flows of discontinued operations</i>	6.3	6.3	6.3	6.3	-	-	-	(6.3)	
<b>Cash flows from investing activities</b>	29.3	10.6	4.1	(0.9)	100.3	216.5	258.7	254.5	
<i>Of which, cash flows of discontinued operations</i>	(1.9)	103.2	103.2	103.2	-	-	-	(103.2)	
<b>Cash flows from financing activities</b>	(34.5)	(35.2)	(46.6)	(47.4)	(12.5)	(13.3)	(25.9)	20.7	
<i>Of which, cash flows of discontinued operations</i>	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	0.0	
Effect of exchange rate changes on cash and cash equivalents	(0.4)	(0.2)	0.1	(0.5)	(1.2)	(1.0)	(0.4)	(0.4)	
Net increase (decrease) in cash and cash equivalents	3.7	(4.9)	(3.8)	4.9	87.2	222.8	264.2	268.0	
Transfer to assets held for sale	(3.6)	-	-	-	-	-	-	-	
Cash and cash equivalents at beginning of period	15.9	15.9	15.9	15.9	20.8	20.8	20.8	4.9	
<b>Cash and cash equivalents at end of period*</b>	15.9	10.9	12.1	20.8	108.0	243.5	285.0	272.9	

\* Cash reserves at end of period

Cash and cash equivalents at end of period	15.9	10.9	12.1	20.8	108.0	243.5	285.0	272.9
+ Loans receivable from parent in excess of three months	144.6	283.7	283.4	285.7	182.4	51.9	-	(283.4)
+ Time deposits whose maturity periods exceed three months	-	0.8	0.8	-	-	-	-	(0.8)
Cash reserves at end of period	160.5	295.4	296.2	306.5	290.4	295.4	285.0	(11.2)

### III. Revenue from Main Products

<Accumulative>

Unit: Billions of yen

Product name		FY 2019 results				FY 2020 results				FY 2020 forecasts	
		Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec	Progress
Japan	Nesp	11.8	25.6	32.0	33.6	1.2	2.2	3.3	(28.7)	4.6	72%
	Darbepoetin Alfa Injection Syringe [KKF]	-	-	5.6	14.0	6.3	12.4	18.6	13.0	24.4	76%
	Duvroq	-	-	-	-	-	-	0.5	0.5		
	Regpara	1.8	3.8	5.2	6.5	1.0	2.0	2.9	(2.4)	3.3	87%
	Orkedia	1.2	3.0	4.8	6.9	2.0	4.3	6.6	1.7	9.5	69%
	Rocaltrol	0.8	1.7	2.7	3.6	0.8	1.6	2.5	(0.2)	3.3	74%
	Onglyza	1.7	3.7	5.5	7.4	1.6	3.3	5.1	(0.4)	6.9	74%
	Coniel	1.0	2.0	3.0	4.0	0.8	1.6	2.4	(0.6)	3.0	77%
	G-Lasta	5.3	11.5	18.3	24.6	6.1	12.8	19.6	1.2	27.6	71%
	Fentos	1.1	2.3	3.4	4.7	0.9	1.9	2.9	(0.5)	3.9	75%
	Poteligeo	0.4	1.0	1.5	2.0	0.5	1.0	1.5	0.0	2.0	76%
	Rituximab BS [KHK]	1.8	4.2	6.8	9.7	2.6	5.4	8.6	1.8	11.4	75%
	Romiplate	0.8	1.6	3.0	4.9	2.0	4.1	5.8	2.8	7.4	79%
	Allelock	4.0	6.4	8.5	10.8	3.0	4.9	6.5	(1.9)	8.3	79%
	Patanol	8.5	9.9	11.7	13.6	5.9	7.1	8.7	(2.9)	9.8	89%
	Dovobet	1.5	3.4	5.0	6.8	1.6	3.4	5.0	0.1	6.8	73%
	Lumicef	0.5	1.2	1.8	2.5	0.6	1.3	2.0	0.2	2.8	71%
	Nourias	2.2	4.8	7.3	9.7	2.2	4.6	6.9	(0.4)	9.9	70%
	HARUROPI	-	-	-	0.1	0.1	0.2	0.4	0.4	1.1	38%
	Depakene	1.1	2.3	3.3	4.5	1.0	1.9	2.9	(0.5)	3.6	80%
Crysvita	-	-	-	0.1	0.5	1.3	2.4	2.4	3.5	68%	
Technology out-licensing		0.9	1.7	3.7	4.6	0.3	1.0	1.6	(2.1)	3.5	46%
International	Crysvita	5.7	13.4	21.6	32.5	12.0	24.7	38.5	16.9	51.1	75%
	North America		9.9	16.3	25.1	9.2	19.2	30.3	14.0		
	EMEA		3.5	5.3	7.4	2.8	5.6	8.3	3.0		
	Poteligeo	2.4	5.4	8.0	10.8	2.9	5.4	8.4	0.4	10.0	85%
	Nouriaz	-	-	-	0.1	0.4	1.0	1.7	1.7	2.6	65%
	Abstral	3.1	5.8	8.3	11.2	2.8	5.8	7.6	(0.7)	9.7	79%
	Pecfent	1.1	1.9	2.9	4.0	1.0	2.0	3.3	0.4	4.2	78%
	Moventig	0.5	1.0	1.4	2.0	0.6	1.2	1.7	0.3	2.2	78%
	Adcal-D3	0.8	1.6	2.3	3.0	0.9	1.6	2.4	0.0	3.0	78%
	Nesp	1.7	3.3	4.7	6.2	1.6	3.2	4.7	(0.0)	6.3	75%
	Regpara	1.1	2.4	3.8	5.0	1.7	3.9	6.1	2.3	7.4	82%
	Neulasta/Peglata	1.0	1.9	2.7	3.8	1.0	2.0	3.0	0.3	4.1	74%
	Gran	1.5	3.1	4.8	6.4	1.4	2.9	4.4	(0.4)	6.0	74%
Technology out-licensing		3.2	5.2	7.9	13.3	3.1	7.0	10.9	3.0	18.3	60%
Of which, Benralizumab royalty		2.0	3.8	6.1	8.9	2.7	5.2	8.3	2.3		

\* Revenue is classified as Japan or International (other than Japan) based on customer location.

\* Revenue from main products does not include revenue from the Early Access Program (EAP).

\* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

\* Benralizumab royalty only refers to the royalty on sales of Fasenna by AstraZeneca (including the Company's own estimates).

### III. Revenue from Main Products

<Quarterly>

Unit: Billions of yen

Product name		FY 2019 results				FY 2020 results			
		Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Japan	Nesp	11.8	13.8	6.4	1.6	1.2	1.0	1.1	(5.3)
	Darbepoetin Alfa Injection Syringe [KKF]	-	-	5.6	8.4	6.3	6.1	6.2	0.6
	Duvroq	-	-	-	-	-	-	0.5	0.5
	Regpara	1.8	1.9	1.5	1.3	1.0	1.0	0.9	(0.6)
	Orkedia	1.2	1.8	1.8	2.1	2.0	2.3	2.3	0.5
	Rocaltrol	0.8	0.9	0.9	0.9	0.8	0.8	0.9	(0.1)
	Onglyza	1.7	2.0	1.8	2.0	1.6	1.7	1.7	(0.1)
	Coniel	1.0	1.1	0.9	1.0	0.8	0.8	0.7	(0.2)
	G-Lasta	5.3	6.2	6.8	6.3	6.1	6.6	6.8	(0.0)
	Fentos	1.1	1.2	1.1	1.3	0.9	1.0	1.0	(0.1)
	Poteligeo	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.0
	Rituximab BS [KHK]	1.8	2.3	2.6	2.9	2.6	2.9	3.1	0.5
	Romiplate	0.8	0.9	1.3	1.9	2.0	2.1	1.7	0.4
	Allelock	4.0	2.4	2.0	2.3	3.0	1.8	1.7	(0.3)
	Patanol	8.5	1.4	1.7	1.9	5.9	1.3	1.6	(0.1)
	Dovobet	1.5	1.9	1.6	1.8	1.6	1.8	1.6	0.0
	Lumicef	0.5	0.7	0.7	0.7	0.6	0.7	0.7	0.0
	Nourias	2.2	2.6	2.5	2.4	2.2	2.4	2.3	(0.3)
	HARUROPI	-	-	-	0.1	0.1	0.1	0.2	0.2
	Depakene	1.1	1.2	1.1	1.1	1.0	1.0	0.9	(0.1)
Crysvita	-	-	-	0.1	0.5	0.8	1.1	1.1	
Technology out-licensing		0.9	0.7	2.1	0.9	0.3	0.7	0.6	(1.5)
International	Crysvita	5.7	7.7	8.2	10.9	12.0	12.8	13.8	5.6
	North America			6.4	8.8	9.2	10.0	11.1	4.7
	EMEA			1.8	2.1	2.8	2.8	2.7	0.9
	Poteligeo	2.4	3.0	2.6	2.8	2.9	2.4	3.1	0.4
	Nourianz	-	-	-	0.1	0.4	0.6	0.7	0.7
	Abstral	3.1	2.7	2.5	2.9	2.8	3.0	1.9	(0.6)
	Pecfent	1.1	0.9	1.0	1.1	1.0	1.1	1.2	0.3
	Moventig	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.1
	Adcal-D3	0.8	0.8	0.7	0.6	0.9	0.7	0.7	(0.0)
	Nesp	1.7	1.6	1.4	1.5	1.6	1.6	1.5	0.0
	Regpara	1.1	1.3	1.4	1.2	1.7	2.1	2.2	0.8
	Neulasta/Peglasta	1.0	1.0	0.8	1.1	1.0	1.0	1.0	0.3
	Gran	1.5	1.7	1.7	1.6	1.4	1.5	1.5	(0.1)
	Technology out-licensing		3.2	2.0	2.7	5.4	3.1	3.9	4.0
Of which, Benralizumab royalty		2.0	1.8	2.3	2.8	2.7	2.5	3.1	0.8

\* Revenue is classified as Japan or International (other than Japan) based on customer location.

\* Revenue from main products does not include revenue from the Early Access Program (EAP).

\* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

\* Benralizumab royalty only refers to the royalty on sales of Fasentra by AstraZeneca (including the Company's own estimates).

## IV. R&D Pipeline

© New Molecular Entity

Updated since Dec. 31, 2019

Updated since Jun. 30, 2020

antibody protein small molecule

Nephrology

As of Sep. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Hemodialysis)	CN						[Kirin-Amgen]
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN KR TW HK						[Mitsubishi Tanabe Pharma]
©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	JP						[Reata]
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House]
KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	CH SA AU						[In-House] POTELLIGENT®
©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	JP						[Syndax]
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony-Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood	JP						[Kirin-Amgen]
		Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						
©KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	US						[In-House] Combination with KW-0761
		Urothelial carcinoma	US						[In-House] Combination with avelumab
©ME-401 Zandelisib Oral	PI3Kδ Inhibitor	B-cell malignancies	JP US						[MEI Pharma]
		Follicular Lymphoma	US EU AU KR others						

※ Since the development of KW-0761 for Adult T-cell Leukemia/Lymphoma was discontinued, the relevant information was deleted from this table.

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	MO						[Kirin-Amgen]
			CN						
			MY						
		JP	Axial Spondyloarthritis (axSpA)						
			Systemic Sclerosis						
	Palmoplantar Pustulosis								
©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP US CA EU						[In-House] POTELLIGENT® Human Antibody-Producing Technology
©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	US						[In-House] Human Antibody-Producing Technology Jointly Developed with Astellas

## IV. R&D Pipeline

© New Molecular Entity

→ Updated since Dec. 31, 2019

■ Updated since Jun. 30, 2020

Central Nervous System

antibody protein small molecule

As of Sep. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-6002 Istradefylline Oral	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	EU	→					[In-House]
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	JP	→					[In-House] POTELLIGENT®
© KW-6356 Oral	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	JP	→					[In-House]
© KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP EU	→					[Immunas Pharma]

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	TW KW	→					[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
			QA	→					
			OM	→					
			CH HK	→					
			AU	→					
			BH	→					
			CN SA SG	→					
EU	Adult X-linked Hypophosphatemia (XLH)	→							
KR	FGF23-Related Hypophosphatemic Rickets and Osteomalacia	→							
US	Tumor Induced Osteomalacia (TIO)	→							
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	TW	→					[Kirin-Amgen]
			KR	→					
		CN	Idiopathic (Immune) Thrombocytopenic Purpura	→					
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	JP KR TW	→					
			EU	→					